NCT07094698

Brief Summary

Pelvic floor dysfunction is a term used to describe a variety of disorders involving moderate to severe impairment of the pelvic floor muscles. The pelvic floor is a layer of muscle designed to support the abdominal organs and maintain urethral, anal, and vaginal continence. It includes the pubococcygeus, puborectalis, and iliococcygeus muscles. Pelvic floor muscle dysfunction, which causes significant morbidity particularly in women, is associated with stress urinary incontinence, anal and fecal incontinence, pelvic organ prolapse, and sexual dysfunction, all of which can negatively affect quality of life in women. Moreover, various comorbid conditions such as back and neck pain, asthma, cardiovascular diseases, and psychiatric disorders are also associated with pelvic floor dysfunction. In patients diagnosed with lumbar disc herniation, changes in pelvic floor muscle strength have been observed. These changes may be accompanied by urinary and sexual problems. Individuals with low back pain are at twice the risk of urinary incontinence compared to those without back pain, and strengthening of the pelvic floor muscles has been shown to reduce back pain. This study aims to understand the characteristics of transcutaneous sacral nerve stimulation, examine the neurophysiological basis of this treatment method, and evaluate its potential for future innovative approaches.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
2mo left

Started Mar 2025

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress89%
Mar 2025Jul 2026

Study Start

First participant enrolled

March 1, 2025

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

July 23, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 30, 2025

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2026

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2026

Expected
Last Updated

July 30, 2025

Status Verified

July 1, 2025

Enrollment Period

1 year

First QC Date

July 23, 2025

Last Update Submit

July 23, 2025

Conditions

Keywords

sacral stimulationActivities of daily livingsexual function

Outcome Measures

Primary Outcomes (3)

  • Severity of constipation

    Constipation severity will be measured using the Constipation Severity Instrument (CSI). The scale consists of a total of 16 questions. The CSI includes subscales for colonic inertia, stool obstruction, and pain. The score for the colonic inertia subscale ranges from 0 to 29, the stool obstruction subscale from 0 to 28, and the pain subscale from 0 to 16. Therefore, the total possible score on the CSI ranges from 0 to 73. Higher scores on the scale indicate more severe symptoms.

    through study completion, an average of 2 months.

  • Severity of urinary incontinence

    Urinary incontinence will be assessed using the King's Health Questionnaire (KHQ). The questionnaire, which consists of 32 items divided into two parts, is widely used to evaluate the quality of life in patients with incontinence. In addition to two single-item questions addressing general health status and the impact on quality of life, it includes seven multi-item subscales. These subscales are role limitations, physical limitations, social limitations, personal relationships limitations, emotional problems, sleep and energy disturbances related to incontinence, and severity measures of incontinence. The second part consists of an 11-item symptom severity scale that evaluates the presence and severity of urinary symptoms. Scores on the symptom severity scale range from 0 (best) to 30 (worst). Scores for the other KHQ domains range from 0 (best) to 100 (worst).

    through study completion, an average of 2 months.

  • Sexual quality of life

    This scale is a six-point Likert type and consists of 18 items. Each item is expected to be answered based on the respondent's sexual life over the past four weeks. Each item is scored between 1 and 6. The total score on the scale ranges from 18 to 108. A higher score indicates better sexual quality of life.

    through study completion, an average of 2 months.

Study Arms (1)

Sacral stimulation

EXPERIMENTAL

A low-frequency (2-10 Hz) current with a pulse duration of 200 μs will be applied for 30 minutes, 5 days a week, under the supervision of a physiotherapist for 6 weeks.

Other: sacral stimulation

Interventions

A low-frequency (2-10 Hz) current with a pulse duration of 200 μs will be applied for 30 minutes, 5 days a week, under the supervision of a physiotherapist for 6 weeks.

Sacral stimulation

Eligibility Criteria

Age18 Years - 65 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsDue to the nature of the condition being studied, only female participants will be included in the study.
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Having complaints of urinary incontinence Having complaints of low back pain Diagnosed with constipation according to Rome IV criteria Women with pelvic floor dysfunction Being under 65 years of age Having normal mood and memory functions Being able to speak Turkish Being literate Voluntarily agreeing to participate in the study

You may not qualify if:

  • Neuromuscular diseases (such as Multiple Sclerosis, Parkinson's disease, Myasthenia Gravis, etc.) Malignant tumors Diabetes and other serious medical conditions Pelvic radiation, rectal surgery, spinal surgery Hysterectomy Pelvic inflammation Urinary tract infection Vaginitis Pacemaker implantation Pregnancy Cognitive impairment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medipol Acıbadem Regional Hospital

Istanbul, 34718, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Low Back Pain

Condition Hierarchy (Ancestors)

Back PainPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • muhammed fatih kavak, dr

    Uskudar University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Forty female volunteers aged 18 to 65 years with complaints of urinary incontinence will be included. Low-frequency (2-10 Hz) current with a pulse duration of 200 μs will be applied for 30 minutes, 5 days a week, under the supervision of a physiotherapist for 6 weeks.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr.

Study Record Dates

First Submitted

July 23, 2025

First Posted

July 30, 2025

Study Start

March 1, 2025

Primary Completion

March 1, 2026

Study Completion (Estimated)

July 1, 2026

Last Updated

July 30, 2025

Record last verified: 2025-07

Locations